New stocks news | Simai Pharmaceuticals submits application to Hong Kong Stock Exchange

According to the disclosure by the Hong Kong Stock Exchange on November 12, Zhejiang Shima Pharmaceutical Co., Ltd.-B (hereinafter referred to as Shima Pharmaceutical) submitted its application to the main board of the Hong Kong Stock Exchange, with Huatai International as its exclusive sponsor. According to the prospectus, the company was established in 2017 and is a pioneer and global leader in the next generation T cell engager (TCE) therapy. TCE is a bispecific or multispecific antibody that is designed to target tumor cells by simultaneously binding to tumor-associated antigens (TAA) on the tumor cell and receptors on T cells, thereby directing to the tumor tissue and activating T cells to induce targeted cell cytotoxicity. The company early on recognized the differentiated potential of TCE, which is a next-generation immunotherapy aimed at utilizing and guiding the human immune system to fight cancer. As of November 5, 2025, the company has four proprietary clinical-stage candidate drugs, including (i) DNV3, a potential best-in-class T cell modulator targeting LAG3, (ii) SMET12, a potential first-in-class intravenous injection EGFR CD3 TCE, (iii) CMD011, a potential best-in-class GPC3 CD3 TCE, and (iv) CMDE005, a potential first-in-class EGFR CD3 next-generation cloaking TCE. In addition, the company also has two next-generation multi-functional/logic gate-controlled TCE candidate drugs CMDE101 and CMDE102 in the preclinical stage, targeting FOLR1 PD-L1 CD3 and PSMA PD-L1 CD3 respectively.